Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Neutralization assay of In the presence of recombinant mouse M-CSF, recombinant mouse TRANCE/TNFSF11/RANK L induces osteoclast-like cell formation in mouse splenocytes in a dose-dependent manner (orange line), as measured by TRAP (tartrate-resistant acid phosphatase) solution assay. Under these conditions, osteoclast-like cell formation elicited by recombinant mouse TRANCE/TNFSF11/RANK L (30 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-mouse TRANCE/TNFSF11/RANK L Antigen Affinity-purified Polyclonal Antibody (Product # PA5-47641). The ND50 is typically 0.02-0.06 µg/mL.
|Tested species reactivity||Mouse|
|Host / Isotype||Goat / IgG|
|Immunogen||Mouse myeloma cell line NS0-derived recombinant mouse TRANCE/TNFSF11/RANK L Arg72-Asp316|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS with 5% trehalose|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|ELISA (ELISA)||0.1-0.4 µg/ml (Detection), 0.2-0.8 µg/ml (Capture)|
|Immunohistochemistry (IHC)||5-15 µg/ml|
|Neutralization (Neu)||0.02-0.06 µg/ml|
|Western Blot (WB)||0.1 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
In Western blots, less than 5% cross-reactivity with recombinant mouse (rm) CD27, rmCD40, and rmFas is observed and less than 1% cross-reactivity with rmCD30, recombinant human (rh) DR6, rmGITR, rmTNF RI, and rmTNF RII is observed.
Reconstitute at 0.2 mg/mL in sterile PBS.
Endoxin level is <0.10 EU per 1 µg of the antibody by the LAL method.
This gene encodes a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. This protein was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis. Targeted disruption of the related gene in mice led to severe osteopetrosis and a lack of osteoclasts. The deficient mice exhibited defects in early differentiation of T and B lymphocytes, and failed to form lobulo-alveolar mammary structures during pregnancy. Two alternatively spliced transcript variants have been found.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
OPG ligand, TNF-related activation-induced cytokine, osteoclast differentiation factor, osteoprotegerin ligand, receptor activator of NF-kappaB ligand, receptor activator of nuclear factor kappa B ligand, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor ligand superfamily member 11, tumor necrosis factor-related activation-induced cytokine, RP11-86N24.2, CD254, ODF, OPGL, OPTB2, RANKL, TRANCE, hRANKL2, sOdf, TNFSF11
ODF, RANKL, OPGL, Trance, OPG, Ly109l